savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Company profile
Ticker
SVRA
Exchange
Website
CEO
Robert Neville
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADVENTRX PHARMACEUTICALS INC, BIOKEYS PHARMACEUTICALS INC, Mast Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Aravas Inc. • Savara ApS • Drugrecure A/S • Pharmaorigin A/S • SD Pharmaceuticals, Inc. • Aires Pharmaceuticals, Inc. ...
IRS number
841318182
SVRA stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Entry into a Material Definitive Agreement
12 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Departure of Directors or Certain Officers
25 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Savara Announces Pricing of $80 Million Underwritten Offering of Common
13 Jul 23
Transcripts
SVRA
Earnings call transcript
2020 Q2
6 Aug 20
SVRA
Earnings call transcript
2020 Q1
7 May 20
SVRA
Earnings call transcript
2019 Q4
12 Mar 20
SVRA
Earnings call transcript
2019 Q3
7 Nov 19
SVRA
Earnings call transcript
2019 Q2
8 Aug 19
SVRA
Earnings call transcript
2019 Q1
9 May 19
SVRA
Earnings call transcript
2018 Q4
13 Mar 19
SVRA
Earnings call transcript
2018 Q3
7 Nov 18
SVRA
Earnings call transcript
2018 Q2
9 Aug 18
SVRA
Earnings call transcript
2018 Q1
9 May 18
Latest ownership filings
SC 13D/A
Bain Capital Life Sciences Fund II, L.P.
12 Apr 24
3
Anne Erickson
29 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
Zambon SpA
14 Feb 24
SC 13G
PRUDENTIAL FINANCIAL INC
13 Feb 24
SC 13G/A
CAXTON CORP
13 Feb 24
SC 13G
JENNISON ASSOCIATES LLC
8 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
1 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.69 mm | 27.69 mm | 27.69 mm | 27.69 mm | 27.69 mm | 27.69 mm |
Cash burn (monthly) | (no burn) | 7.68 mm | 6.01 mm | 4.44 mm | 4.39 mm | 3.68 mm |
Cash used (since last report) | n/a | 51.17 mm | 40.08 mm | 29.57 mm | 29.23 mm | 24.49 mm |
Cash remaining | n/a | -23.48 mm | -12.39 mm | -1.88 mm | -1.54 mm | 3.20 mm |
Runway (months of cash) | n/a | -3.1 | -2.1 | -0.4 | -0.4 | 0.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 89 |
Opened positions | 20 |
Closed positions | 10 |
Increased positions | 40 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 440.04 bn |
Total shares | 182.50 mm |
Total puts | 1.20 k |
Total calls | 65.50 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
NEA Management | 24.47 mm | $92.50 bn |
Growth Equity Opportunities 17 | 24.47 mm | $76.84 mm |
Bain Capital Life Sciences Investors | 14.23 mm | $53.80 bn |
Bain Capital Life Sciences Fund II | 14.23 mm | $44.69 mm |
Farallon Capital Management | 10.91 mm | $41.23 bn |
Farallon Capital Partners | 10.72 mm | $0.00 |
TCG Crossover GP I | 10.00 mm | $31.40 mm |
TCG Crossover Management | 10.00 mm | $37.80 bn |
Adage Capital Partners GP, L.L.C. | 7.94 mm | $30.01 bn |
VR Adviser | 7.18 mm | $27.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 23 | Nevan C Elam | Common Stock | Sell | Dispose S | No | No | 4.7131 | 93,843 | 442.29 k | 22,500 |
28 Dec 23 | Nevan C Elam | Common Stock | Option exercise | Acquire M | No | No | 1.23 | 40,000 | 49.20 k | 116,343 |
28 Dec 23 | Nevan C Elam | Common Stock | Option exercise | Acquire M | No | No | 1.59 | 12,000 | 19.08 k | 76,343 |
28 Dec 23 | Nevan C Elam | Common Stock | Option exercise | Acquire M | No | No | 0.82 | 1,758 | 1.44 k | 64,343 |
28 Dec 23 | Nevan C Elam | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.23 | 40,000 | 49.20 k | 0 |
28 Dec 23 | Nevan C Elam | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.59 | 12,000 | 19.08 k | 0 |
28 Dec 23 | Nevan C Elam | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.82 | 1,758 | 1.44 k | 0 |
28 Dec 23 | David L Lowrance | Common Stock | Sell | Dispose S | No | No | 4.7131 | 10,000 | 47.13 k | 342,355 |
28 Dec 23 | Matthew Pauls | Common Stock | Gift | Dispose G | No | No | 0 | 19,000 | 0.00 | 1,283,674 |
28 Dec 23 | Matthew Pauls | Common Stock | Sell | Dispose S | No | No | 4.7131 | 84,000 | 395.90 k | 1,302,674 |
News
JMP Securities Reiterates Market Outperform on Savara, Maintains $8 Price Target
18 Apr 24
Savara To Present New Data On Autoimmune Pulmonary Alveolar Proteinosis At The American Thoracic Society International Conference 2024
8 Apr 24
HC Wainwright & Co. Reiterates Buy on Savara, Maintains $6 Price Target
11 Mar 24
Savara Q4 EPS $(0.09) Beats $(0.10) Estimate
7 Mar 24
Piper Sandler Maintains Overweight on Savara, Raises Price Target to $16
4 Mar 24
Press releases
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
8 Apr 24
Savara Announces New Employment Inducement Grant
22 Mar 24
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
7 Mar 24
Savara Announces New Employment Inducement Grant
2 Feb 24
Savara to Present at Two Upcoming Healthcare Conferences
31 Jan 24